Neurological immune-related adverse events of ipilimumab

Practical Neurology

Volumn 13, Issue 4, 2013, Pages 278-280

  Bot, Ilja ^a,b   Blank, Christian U ^a   Boogerd, Willem ^a   Brandsma, Dieta ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOLOGIC FACTOR; IPILIMUMAB; MONOCLONAL ANTIBODY;

AGED; ARTICLE; CASE REPORT; HUMAN; IMMUNOLOGY; MALE; MELANOMA; MIDDLE AGED; NEUROONCOLOGY; NEUROPHARMACOLOGY;

NEUROONCOLOGY; NEUROPHARMACOLOGY;

AGED; ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; HUMANS; IMMUNOLOGIC FACTORS; MALE; MELANOMA; MIDDLE AGED;

EID: 84879977559     PISSN: 14747758     EISSN: 14747766     Source Type: Journal    
DOI: 10.1136/practneurol-2012-000447     Document Type: Article

References (15)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
3. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009;58:823-30.
4. Dillard T, Yedinak CG, Alumkal J, et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010;13:29-38.
5. Ezzat S, Josse RG. Autoimmune hypophysitis. Trends Endocrinol Metab 1997;8:74-80.
6. Carpenter KJ, Murtagh RD, Lilienfeld H, et al. Ipilimumabinduced hypophysitis: MR imaging findings. AJNR Am J Neuroradiol 2009;30:1751-3.
7. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30:825-30.
8. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyteassociated antigen 4. J Clin Oncol 2006;24:2283-9.
9. Csurhes PA, Sullivan AA, Green K, et al. Increased circulating T cell reactivity to GM1 ganglioside in patients with Guillain-Barré syndrome. J Clin Neurosci 2005;12: 409-15.
10. De JJ, Carmignac D, Le TP, et al. Factors affecting the susceptibility of the mouse pituitary gland to CD8 T-cell-mediated autoimmunity. Immunology 2004;111: 254-61.
11. Perrin PJ, Lavi E, Rumbley CA, et al. Experimental autoimmune meningitis: a novel neurological disease in CD28-deficient mice. Clin Immunol 1999;91:41-9.
12. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol 2011;22:991-3.
13. Bompaire F, Mateus C, Taillia H, et al. Severe meningo-radiculo-nevritis associated with ipilimumab. Invest New Drugs 2012.
14. Hunter G, Voll C, Robinson CA. Autoimmune inflammatory myopathy after treatment with ipilimumab. Can J Neurol Sci 2009;36:518-20.
15. Bhatia S, Huber BR, Upton MP, et al. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report. J Immunother 2009;32:203-5.